NOT FOR DISTRIBUTION
Header cover image

Market Cap

US$133.1m

Last Updated

2021/05/11 22:52 UTC

Data Sources

Company Financials +

Executive Summary

Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. More Details


Snowflake Analysis

Excellent balance sheet with reasonable growth potential.


Similar Companies

Share Price & News

How has Champions Oncology's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CSBR is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: CSBR's weekly volatility (9%) has been stable over the past year.


Market Performance


7 Day Return

-3.5%

CSBR

-3.0%

US Life Sciences

-1.2%

US Market


1 Year Return

14.5%

CSBR

47.0%

US Life Sciences

48.3%

US Market

Return vs Industry: CSBR underperformed the US Life Sciences industry which returned 47% over the past year.

Return vs Market: CSBR underperformed the US Market which returned 48.3% over the past year.


Shareholder returns

CSBRIndustryMarket
7 Day-3.5%-3.0%-1.2%
30 Day-12.2%-2.6%0.2%
90 Day-13.6%-4.8%1.6%
1 Year14.5%14.5%47.2%47.0%50.8%48.3%
3 Year138.9%138.9%104.3%103.2%62.0%51.9%
5 Year148.5%148.5%210.0%206.3%126.9%101.7%

Long-Term Price Volatility Vs. Market

How volatile is Champions Oncology's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Champions Oncology undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: CSBR ($9.94) is trading below our estimate of fair value ($29.22)

Significantly Below Fair Value: CSBR is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: CSBR is unprofitable, so we can't compare its PE Ratio to the US Life Sciences industry average.

PE vs Market: CSBR is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CSBR's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CSBR is overvalued based on its PB Ratio (16.9x) compared to the US Life Sciences industry average (7.1x).


Future Growth

How is Champions Oncology forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

153.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CSBR is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).

Earnings vs Market: CSBR is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: CSBR's is expected to become profitable in the next 3 years.

Revenue vs Market: CSBR's revenue (18.4% per year) is forecast to grow faster than the US market (9% per year).

High Growth Revenue: CSBR's revenue (18.4% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if CSBR's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Champions Oncology performed over the past 5 years?

57.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CSBR is currently unprofitable.

Growing Profit Margin: CSBR is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CSBR is unprofitable, but has reduced losses over the past 5 years at a rate of 57.1% per year.

Accelerating Growth: Unable to compare CSBR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CSBR is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (17.4%).


Return on Equity

High ROE: CSBR has a negative Return on Equity (-15.65%), as it is currently unprofitable.


Financial Health

How is Champions Oncology's financial position?


Financial Position Analysis

Short Term Liabilities: CSBR's short term assets ($14.0M) exceed its short term liabilities ($11.4M).

Long Term Liabilities: CSBR's short term assets ($14.0M) exceed its long term liabilities ($6.0M).


Debt to Equity History and Analysis

Debt Level: CSBR is debt free.

Reducing Debt: CSBR currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CSBR has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if CSBR has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is Champions Oncology current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CSBR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CSBR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CSBR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CSBR's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CSBR's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.3yrs

Average management tenure


CEO

Ronnie Morris (54 yo)

4.33yrs

Tenure

US$1,343,653

Compensation

Dr. Ronnie Morris, M.D. has been Chief Executive Officer at Champions Oncology, Inc. since January 31, 2017. Dr. Morris previously served as the President and a Director of Champions Oncology, Inc. from Oc...


CEO Compensation Analysis

Compensation vs Market: Ronnie's total compensation ($USD1.34M) is above average for companies of similar size in the US market ($USD534.69K).

Compensation vs Earnings: Ronnie's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: CSBR's management team is considered experienced (3.3 years average tenure).


Board Members

Experienced Board: CSBR's board of directors are considered experienced (5.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 12.6%.


Top Shareholders

Company Information

Champions Oncology, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Champions Oncology, Inc.
  • Ticker: CSBR
  • Exchange: NasdaqCM
  • Founded: 1985
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$133.098m
  • Shares outstanding: 13.39m
  • Website: https://www.championsoncology.com

Number of Employees


Location

  • Champions Oncology, Inc.
  • One University Plaza
  • Suite 307
  • Hackensack
  • New Jersey
  • 7601
  • United States

Listings


Biography

Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approac...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/05/11 22:52
End of Day Share Price2021/05/11 00:00
Earnings2021/01/31
Annual Earnings2020/04/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.